Table 1 Baseline features of AML studied cases
Patient characteristics | Frequency (%) | Patient characteristics | Frequency (%) |
|---|---|---|---|
Age (years) | 48 ± 14 | Immunophenotyping | |
Gender (male/female) | 49/31 | Positive CD34 | 43 (53.8) |
Initial TLC (median and range) × 103/mm3 | 22.5 (0.3–403) | Positive HLA-DR | 45 (56.3) |
Initial HGB (median and range) g/dl | 7.8 ± 1.9 | Positive MPO (cyto) | 68 (85) |
Initial PLT (median and range) × 103/mm3 | 45 (4–208) | Positive CD33 | 71 (88.8) |
Initial PB Blasts (median and range)% | 60 (0–100) | Positive CD13 | 67 (83.8) |
Initial BMA Blast (median and range)% | 73 (20–98) | Positive CD117 | 59 (73.8) |
Hepatomegaly | 16 (20) | Positive CD14 | 16 (20) |
Splenomegaly | 16 (20) | Positive CD4 | 7 (8.8) |
Lymphadenopathy | 27 (33.8) | Positive CD11c | 19 (23.8) |
Fever | 37 (46.3) | Positive CD64 | 25 (31.3) |
Initial cellularity | Positive CD61 | 2 (2.5) | |
Hypocellularity | 2 (2.5) | Positive CD7 | 5 (6.3) |
Hypercellularity | 67 (83.8) | Cytogenetics | |
Normocellularity | 11 (13.8) | Abnormal Cytogenetics | 37 (53.6) |
FAB subtypes | Negative FLT-ITD | 61 (76.3) | |
M0 | 2 (2.5) | Positive FLT-ITD | 19 (23.8) |
M1 | 13 (16.3) | Wild NPM | 74 (92.5) |
M2 | 30 (37.5) | Mutant NPM | 6 (7.5) |
M3 | 8 (10) | t(8;21) | 5 (6.3) |
M4 | 18 (22.5) | PML/RARA | 7 (8.8) |
M5 | 7 (8.8) | t(16;16)/inv16 | 2 (2.5) |
M7 | 2 (2.5) | t(9;22) | 2 (2.5) |
Genetic risk (ELN 2017) | Treatment response | ||
Favorable | 19 (23.8) | BMA blast on day 14 | 2 (0–90) |
Median (min–max) | |||
Intermediate | 36 (45) | BMA blast on day 28 | 2 (0–88) |
Median (min–max) | |||
Poor | 25 (31.3) |